ELK GROVE VILLAGE, Ill--SoloPak Pharmaceuticals, Inc. has signed
an agreement with Sloan-Kettering Institute for Cancer Research
to acquire the exclusive worldwide rights to gallium nitrate (Ganite),
which was FDA approved in 1991 for the treatment of acute hypercalcemia
in cancer patients and had been manufactured by Fujisawa USA (Deerfield,
The agreement involves a grant of SoloPak equity to the Institute
and a commitment of funds from SoloPak to complete clinical trials.
Over the next 2 to 3 years, SoloPak plans to seek approval of
gallium nitrate for the treatment of chronic hypercalcemia and
bone metastases in cancer patients, and to launch clinical trials
of the agent in Paget's disease and osteoporosis.